Consensus $866.53M. The company said, “Increasing 2025 financial guidance reflects strong overall revenue performance experienced year-to-date and fourth quarter outlook, including strong momentum seen with TRYNGOLZA revenues.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals reports Q3 EPS (80c), consensus ($1.05)
- AMZN, BABA, NTLA, XYZ: Cathie Wood Loads Up on Intellia, Block, Amazon & Alibaba, Cuts Stake in Shopify and Other Growth Stocks
- Ionis Pharmaceuticals’ Phase 3 Study on Angelman Syndrome: A Potential Game-Changer
- Ionis Pharmaceuticals Advances in MECP2 Duplication Syndrome Treatment
- Ionis Pharmaceuticals’ HALOS Study: A New Hope for Angelman Syndrome